Literature DB >> 23576504

Sustained hyperresponsiveness of dendritic cells is associated with spontaneous resolution of acute hepatitis C.

Sandy Pelletier1, Nathalie Bédard, Elias Said, Petronela Ancuta, Julie Bruneau, Naglaa H Shoukry.   

Abstract

Some studies have reported that dendritic cells (DCs) may be dysfunctional in a subset of patients with chronic hepatitis C virus (HCV) infection. However, the function of DCs during acute HCV infection and their role in determining infectious outcome remain elusive. Here, we examined the phenotype and function of myeloid DCs (mDCs) and plasmacytoid DCs (pDCs) during acute HCV infection. Three groups of injection drug users (IDUs) at high risk of HCV infection were studied: an uninfected group, a group with acute HCV infection with spontaneous resolution, and a group with acute infection with chronic evolution. We examined the frequency, maturation status, and cytokine production capacity of DCs in response to the Toll-like receptor 4 (TLR4) and TLR7/8 ligands lipopolysaccharide (LPS) and single-stranded RNA (ssRNA), respectively. Several observations could distinguish HCV-negative IDUs and acute HCV resolvers from patients with acute infection with chronic evolution. First, we observed a decrease in the frequency of mature CD86(+), programmed death-1 receptor ligand-positive (PDL1(+)), and PDL2(+) pDCs. This phenotype was associated with the increased sensitivity of pDCs from resolvers and HCV-negative IDUs versus the group with acute infection with chronic evolution to ssRNA stimulation in vitro. Second, LPS-stimulated mDCs from resolvers and HCV-negative IDUs produced higher levels of cytokines than mDCs from the group with acute infection with chronic evolution. Third, mDCs from all patients with acute HCV infection, irrespective of their outcomes, produced higher levels of cytokines during the early acute phase in response to ssRNA than mDCs from healthy controls. However, this hyperresponsiveness was sustained only in spontaneous resolvers. Altogether, our results suggest that the immature pDC phenotype and sustained pDC and mDC hyperresponsiveness are associated with spontaneous resolution of acute HCV infection.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23576504      PMCID: PMC3676083          DOI: 10.1128/JVI.02445-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

Review 1.  Inflammatory signals in dendritic cell activation and the induction of adaptive immunity.

Authors:  Olivier Joffre; Martijn A Nolte; Roman Spörri; Caetano Reis e Sousa
Journal:  Immunol Rev       Date:  2009-01       Impact factor: 12.988

2.  Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis C.

Authors:  Randy S Longman; Andrew H Talal; Ira M Jacobson; Charles M Rice; Matthew L Albert
Journal:  J Infect Dis       Date:  2005-06-27       Impact factor: 5.226

3.  Increased degranulation of natural killer cells during acute HCV correlates with the magnitude of virus-specific T cell responses.

Authors:  Sandy Pelletier; Christian Drouin; Nathalie Bédard; Salim I Khakoo; Julie Bruneau; Naglaa H Shoukry
Journal:  J Hepatol       Date:  2010-07-17       Impact factor: 25.083

4.  Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression.

Authors:  Henry Radziewicz; Chris C Ibegbu; Marina L Fernandez; Kimberly A Workowski; Kamil Obideen; Mohammad Wehbi; Holly L Hanson; James P Steinberg; David Masopust; E John Wherry; John D Altman; Barry T Rouse; Gordon J Freeman; Rafi Ahmed; Arash Grakoui
Journal:  J Virol       Date:  2006-12-20       Impact factor: 5.103

5.  SPICE: exploration and analysis of post-cytometric complex multivariate datasets.

Authors:  Mario Roederer; Joshua L Nozzi; Martha C Nason
Journal:  Cytometry A       Date:  2011-01-07       Impact factor: 4.355

6.  Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation.

Authors:  Angela Dolganiuc; Shilpa Oak; Karen Kodys; Douglas T Golenbock; Robert W Finberg; Evelyn Kurt-Jones; Gyongyi Szabo
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

7.  Reduced numbers and impaired ability of myeloid and plasmacytoid dendritic cells to polarize T helper cells in chronic hepatitis C virus infection.

Authors:  Tatsuya Kanto; Michiyo Inoue; Hideki Miyatake; Aki Sato; Mitsuru Sakakibara; Takayuki Yakushijin; Chika Oki; Ichiyo Itose; Naoki Hiramatsu; Tetsuo Takehara; Akinori Kasahara; Norio Hayashi
Journal:  J Infect Dis       Date:  2004-10-27       Impact factor: 5.226

Review 8.  Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence.

Authors:  Barbara Rehermann
Journal:  J Clin Invest       Date:  2009-07-01       Impact factor: 14.808

9.  Regulatory T cells in hepatitis C virus infection.

Authors:  Kyong-Mi Chang
Journal:  Hepatol Res       Date:  2007-10       Impact factor: 4.288

10.  Presence of functional dendritic cells in patients chronically infected with hepatitis C virus.

Authors:  Randy S Longman; Andrew H Talal; Ira M Jacobson; Matthew L Albert; Charles M Rice
Journal:  Blood       Date:  2003-10-02       Impact factor: 22.113

View more
  10 in total

1.  Toll-Like Receptor 7 (TLR-7) and TLR-9 Agonists Improve Hepatitis C Virus Replication and Infectivity Inhibition by Plasmacytoid Dendritic Cells.

Authors:  B Dominguez-Molina; K Machmach; C Perales; L Tarancon-Diez; I Gallego; J L Sheldon; M Leal; E Domingo; E Ruiz-Mateos
Journal:  J Virol       Date:  2018-11-12       Impact factor: 5.103

Review 2.  Vitamin D and chronic hepatitis C: effects on success rate and prevention of side effects associated with pegylated interferon-α and ribavirin.

Authors:  Bassem Refaat; Adel Galal El-Shemi; Ahmed Ashshi; Esam Azhar
Journal:  Int J Clin Exp Med       Date:  2015-07-15

3.  Role of dendritic cells in the pathogenesis of Whipple's disease.

Authors:  Katina Schinnerling; Anika Geelhaar-Karsch; Kristina Allers; Julian Friebel; Kristina Conrad; Christoph Loddenkemper; Anja A Kühl; Ulrike Erben; Ralf Ignatius; Verena Moos; Thomas Schneider
Journal:  Infect Immun       Date:  2014-11-10       Impact factor: 3.441

Review 4.  Current progress in host innate and adaptive immunity against hepatitis C virus infection.

Authors:  Jijing Shi; Yuanyuan Li; Wenxian Chang; Xuexiu Zhang; Fu-Sheng Wang
Journal:  Hepatol Int       Date:  2017-06-22       Impact factor: 6.047

Review 5.  Innate and Adaptive Immune Responses in Chronic HCV Infection.

Authors:  Lynn B Dustin
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

6.  Sex Differences in monocytes and TLR4 associated immune responses; implications for systemic lupus erythematosus (SLE).

Authors:  Wei Jiang; Gary Gilkeson
Journal:  J Immunother Appl       Date:  2014-03-07

Review 7.  Activins and Follistatin in Chronic Hepatitis C and Its Treatment with Pegylated-Interferon-α Based Therapy.

Authors:  Bassem Refaat; Ahmed Mohamed Ashshi; Adel Galal El-Shemi; Esam Azhar
Journal:  Mediators Inflamm       Date:  2015-04-19       Impact factor: 4.711

Review 8.  Protective immunity against hepatitis C: many shades of gray.

Authors:  Mohamed S Abdel-Hakeem; Naglaa H Shoukry
Journal:  Front Immunol       Date:  2014-06-16       Impact factor: 7.561

Review 9.  Viruses Seen by Our Cells: The Role of Viral RNA Sensors.

Authors:  Elias A Said; Nicolas Tremblay; Mohammed S Al-Balushi; Ali A Al-Jabri; Daniel Lamarre
Journal:  J Immunol Res       Date:  2018-04-30       Impact factor: 4.818

10.  Immune Correlates of Natural HIV Elite Control and Simultaneous HCV Clearance-Supercontrollers.

Authors:  Beatriz Dominguez-Molina; Sara Ferrando-Martinez; Laura Tarancon-Diez; Jose Hernandez-Quero; Miguel Genebat; Francisco Vidal; Mª Angeles Muñoz-Fernandez; Manuel Leal; Richard Koup; Ezequiel Ruiz-Mateos
Journal:  Front Immunol       Date:  2018-12-10       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.